Real-world data on the effectiveness of risankizumab as induction therapy for ustekinumab-refractory ulcerative colitis.

Morikawa R, Fujii T, Tamura A, Kawamoto A, Hibiya S, Takenaka K, Shimizu H, Ohtsuka K, Okamoto R

Open source

DOI
10.5217/ir.2025.00338
Published
2026 Aug 10
Container
Intestinal research
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.5217/ir.2025.00338,
  title = {Real-world data on the effectiveness of risankizumab as induction therapy for ustekinumab-refractory ulcerative colitis.},
  author = {Morikawa R and Fujii T and Tamura A and Kawamoto A and Hibiya S and Takenaka K and Shimizu H and Ohtsuka K and Okamoto R},
  year = {2026},
  journal = {Intestinal research},
  doi = {10.5217/ir.2025.00338},
  url = {https://doi.org/10.5217/ir.2025.00338}
}

RIS

TY  - JOUR
TI  - Real-world data on the effectiveness of risankizumab as induction therapy for ustekinumab-refractory ulcerative colitis.
AU  - Morikawa R
AU  - Fujii T
AU  - Tamura A
AU  - Kawamoto A
AU  - Hibiya S
AU  - Takenaka K
AU  - Shimizu H
AU  - Ohtsuka K
AU  - Okamoto R
PY  - 2026
JO  - Intestinal research
DO  - 10.5217/ir.2025.00338
UR  - https://doi.org/10.5217/ir.2025.00338
ER  - 

APA

R, M., T, F., A, T., A, K., S, H., K, T., H, S., K, O., & R, O. (2026). Real-world data on the effectiveness of risankizumab as induction therapy for ustekinumab-refractory ulcerative colitis.. Intestinal research. https://doi.org/10.5217/ir.2025.00338

Source records